326 related articles for article (PubMed ID: 33203692)
1. Genetic Predictors of Severe Skin Toxicity in Patients with Stage III Colon Cancer Treated with Cetuximab: NCCTG N0147 (Alliance).
Labadie JD; Hua X; Harrison TA; Banbury BL; Huyghe JR; Sun W; Shi Q; Yothers G; Alberts SR; Sinicrope FA; Goldberg RM; George TJ; Penney KL; Phipps AI; Cohen SA; Peters U; Chan AT; Newcomb PA
Cancer Epidemiol Biomarkers Prev; 2021 Feb; 30(2):404-411. PubMed ID: 33203692
[TBL] [Abstract][Full Text] [Related]
2. Comparison of FOLFIRI with or without cetuximab in patients with resected stage III colon cancer; NCCTG (Alliance) intergroup trial N0147.
Huang J; Nair SG; Mahoney MR; Nelson GD; Shields AF; Chan E; Goldberg RM; Gill S; Kahlenberg MS; Quesenberry JT; Thibodeau SN; Smyrk TC; Grothey A; Sinicrope FA; Webb TA; Farr GH; Pockaj BA; Berenberg JL; Mooney M; Sargent DJ; Alberts SR;
Clin Colorectal Cancer; 2014 Jun; 13(2):100-9. PubMed ID: 24512953
[TBL] [Abstract][Full Text] [Related]
3. Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy: A Pooled Analysis From 2 Randomized Clinical Trials.
Zaanan A; Shi Q; Taieb J; Alberts SR; Meyers JP; Smyrk TC; Julie C; Zawadi A; Tabernero J; Mini E; Goldberg RM; Folprecht G; Van Laethem JL; Le Malicot K; Sargent DJ; Laurent-Puig P; Sinicrope FA
JAMA Oncol; 2018 Mar; 4(3):379-383. PubMed ID: 28983557
[TBL] [Abstract][Full Text] [Related]
4. Genome wide association study to identify predictors for severe skin toxicity in colorectal cancer patients treated with cetuximab.
Baas J; Krens L; Bohringer S; Mol L; Punt C; Guchelaar HJ; Gelderblom H
PLoS One; 2018; 13(12):e0208080. PubMed ID: 30557370
[TBL] [Abstract][Full Text] [Related]
5. DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG N0147).
Lee AM; Shi Q; Pavey E; Alberts SR; Sargent DJ; Sinicrope FA; Berenberg JL; Goldberg RM; Diasio RB
J Natl Cancer Inst; 2014 Dec; 106(12):. PubMed ID: 25381393
[TBL] [Abstract][Full Text] [Related]
6. Association between DPYD c.1129-5923 C>G/hapB3 and severe toxicity to 5-fluorouracil-based chemotherapy in stage III colon cancer patients: NCCTG N0147 (Alliance).
Lee AM; Shi Q; Alberts SR; Sargent DJ; Sinicrope FA; Berenberg JL; Grothey A; Polite B; Chan E; Gill S; Kahlenberg MS; Nair SG; Shields AF; Goldberg RM; Diasio RB
Pharmacogenet Genomics; 2016 Mar; 26(3):133-7. PubMed ID: 26658227
[TBL] [Abstract][Full Text] [Related]
7. Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial.
Alberts SR; Sargent DJ; Nair S; Mahoney MR; Mooney M; Thibodeau SN; Smyrk TC; Sinicrope FA; Chan E; Gill S; Kahlenberg MS; Shields AF; Quesenberry JT; Webb TA; Farr GH; Pockaj BA; Grothey A; Goldberg RM
JAMA; 2012 Apr; 307(13):1383-93. PubMed ID: 22474202
[TBL] [Abstract][Full Text] [Related]
8. Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
Taieb J; Tabernero J; Mini E; Subtil F; Folprecht G; Van Laethem JL; Thaler J; Bridgewater J; Petersen LN; Blons H; Collette L; Van Cutsem E; Rougier P; Salazar R; Bedenne L; Emile JF; Laurent-Puig P; Lepage C;
Lancet Oncol; 2014 Jul; 15(8):862-73. PubMed ID: 24928083
[TBL] [Abstract][Full Text] [Related]
9. Genetic Variant Associated With Survival of Patients With Stage II-III Colon Cancer.
Penney KL; Banbury BL; Bien S; Harrison TA; Hua X; Phipps AI; Sun W; Song M; Joshi AD; Alberts SR; Allegra CJ; Atkins J; Colangelo LH; George TJ; Goldberg RM; Lucas PC; Nair SG; Shi Q; Sinicrope FA; Wolmark N; Yothers G; Peters U; Newcomb PA; Chan AT
Clin Gastroenterol Hepatol; 2020 Nov; 18(12):2717-2723.e3. PubMed ID: 31811950
[TBL] [Abstract][Full Text] [Related]
10. N0147: a randomized phase III trial of oxaliplatin plus 5-fluorouracil/leucovorin with or without cetuximab after curative resection of stage III colon cancer.
Alberts SR; Sinicrope FA; Grothey A
Clin Colorectal Cancer; 2005 Sep; 5(3):211-3. PubMed ID: 16197625
[No Abstract] [Full Text] [Related]
11. Genome-wide study of genetic polymorphisms predictive for outcome from first-line oxaliplatin-based chemotherapy in colorectal cancer patients.
Park HA; Edelmann D; Canzian F; Seibold P; Harrison TA; Hua X; Shi Q; Silverman A; Benner A; Macauda A; Schneider M; Goldberg RM; Alberts SR; Hoffmeister M; Brenner H; Chan AT; Peters U; Newcomb PA; Chang-Claude J
Int J Cancer; 2023 Nov; 153(9):1623-1634. PubMed ID: 37539667
[TBL] [Abstract][Full Text] [Related]
12. Associations between cigarette smoking status and colon cancer prognosis among participants in North Central Cancer Treatment Group Phase III Trial N0147.
Phipps AI; Shi Q; Newcomb PA; Nelson GD; Sargent DJ; Alberts SR; Limburg PJ
J Clin Oncol; 2013 Jun; 31(16):2016-23. PubMed ID: 23547084
[TBL] [Abstract][Full Text] [Related]
13. Relationship Between Metformin Use and Recurrence and Survival in Patients With Resected Stage III Colon Cancer Receiving Adjuvant Chemotherapy: Results From North Central Cancer Treatment Group N0147 (Alliance).
Singh PP; Shi Q; Foster NR; Grothey A; Nair SG; Chan E; Shields AF; Goldberg RM; Gill S; Kahlenberg MS; Sinicrope FA; Sargent DJ; Alberts SR
Oncologist; 2016 Dec; 21(12):1509-1521. PubMed ID: 27881709
[TBL] [Abstract][Full Text] [Related]
14. KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance).
Yoon HH; Tougeron D; Shi Q; Alberts SR; Mahoney MR; Nelson GD; Nair SG; Thibodeau SN; Goldberg RM; Sargent DJ; Sinicrope FA;
Clin Cancer Res; 2014 Jun; 20(11):3033-43. PubMed ID: 24687927
[TBL] [Abstract][Full Text] [Related]
15. Association of DNA Mismatch Repair and Mutations in BRAF and KRAS With Survival After Recurrence in Stage III Colon Cancers : A Secondary Analysis of 2 Randomized Clinical Trials.
Sinicrope FA; Shi Q; Allegra CJ; Smyrk TC; Thibodeau SN; Goldberg RM; Meyers JP; Pogue-Geile KL; Yothers G; Sargent DJ; Alberts SR
JAMA Oncol; 2017 Apr; 3(4):472-480. PubMed ID: 28006055
[TBL] [Abstract][Full Text] [Related]
16. Survival predictors and outcomes of patients with recurrent and/or metastatic head and neck cancer treated with chemotherapy plus cetuximab as first-line therapy: A real-world retrospective study.
Pontes F; Garcia AR; Domingues I; João Sousa M; Felix R; Amorim C; Salgueiro F; Mariano M; Teixeira M
Cancer Treat Res Commun; 2021; 27():100375. PubMed ID: 33882378
[TBL] [Abstract][Full Text] [Related]
17. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial.
de Gramont A; Van Cutsem E; Schmoll HJ; Tabernero J; Clarke S; Moore MJ; Cunningham D; Cartwright TH; Hecht JR; Rivera F; Im SA; Bodoky G; Salazar R; Maindrault-Goebel F; Shacham-Shmueli E; Bajetta E; Makrutzki M; Shang A; André T; Hoff PM
Lancet Oncol; 2012 Dec; 13(12):1225-33. PubMed ID: 23168362
[TBL] [Abstract][Full Text] [Related]
18. Comparison of adverse events during 5-fluorouracil versus 5-fluorouracil/oxaliplatin adjuvant chemotherapy for stage III colon cancer: a population-based analysis.
Sanoff HK; Carpenter WR; Freburger J; Li L; Chen K; Zullig LL; Goldberg RM; Schymura MJ; Schrag D
Cancer; 2012 Sep; 118(17):4309-20. PubMed ID: 22294436
[TBL] [Abstract][Full Text] [Related]
19. A new look at the International Duration Evaluation of Adjuvant therapy (IDEA) classification-Defining novel predictive and prognostic markers in stage III colon cancer.
Margalit O; Mamtani R; Yang YX; Reiss KA; Golan T; Halpern N; Aderka D; Giantonio B; Shacham-Shmueli E; Boursi B
Eur J Cancer; 2018 Jun; 96():105-110. PubMed ID: 29698932
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of a Comprehensive Skin Toxicity Program for Patients Treated With Epidermal Growth Factor Receptor Inhibitors at a Cancer Treatment Center.
Yu Z; Dee EC; Bach DQ; Mostaghimi A; LeBoeuf NR
JAMA Dermatol; 2020 Oct; 156(10):1079-1085. PubMed ID: 32609305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]